Keratoconus referral pathways in New Zealand: a guide for optometrists and GPs

Jagrut Lallu — BOptom (Hons), MSc Specialty Lenses (Hons), FIAOMC. Therapeutic Optometrist & Contact Lens Specialist. Founder, New Zealand Eye Research Centre; Partner, Rose Optometry; WCO Asia-Pacific Myopia Ambassador; International Myopia Institute NZ Ambassador; Clinical Senior Lecturer, Deakin School of Optometry; Honorary Teaching Fellow, University of Auckland.
Corneal cross-linking (CXL) is the only widely used treatment intended to slow the progression of keratoconus, and because it aims to stabilise the cornea rather than reverse existing change, it is most useful before significant vision has been lost. That makes the timing of referral one of the most consequential decisions in keratoconus care, and it usually sits with an optometrist or GP rather than a corneal surgeon. This guide summarises what the evidence and expert consensus say about defining progression, what a useful referral contains, which patients need to be seen urgently, and how public and private pathways work in New Zealand. It is written for clinicians and is not a substitute for local referral criteria.
Defining progression: what the consensus says
The most widely cited reference point is the Global Consensus on Keratoconus and Ectatic Diseases, a Delphi exercise in which 36 ophthalmology experts, split into panels on diagnosis, non-surgical management and surgery, worked through three questionnaire rounds and a face-to-face meeting, with two-thirds agreement required for consensus. The panel described progression as a consistent change in at least two of three parameters: steepening of the anterior corneal surface, steepening of the posterior corneal surface, and thinning of the cornea or a faster rate of thickness change from the periphery to the thinnest point. Importantly, the change has to be larger than the normal measurement noise of the instrument used, and the panel did not agree on fixed numerical thresholds.
Two practical points follow. First, a single parameter, such as maximum keratometry (Kmax) alone, is a weak basis for a decision. Second, because noise differs between devices, comparisons are only meaningful when sequential scans come from the same instrument, ideally with repeat captures at each visit. Our post on advanced corneal imaging and keratoconus monitoring covers the measurement side in more detail.
When to refer for cross-linking
Documented progression is the usual trigger for a CXL referral. The randomised evidence supports this. In a Melbourne trial of 100 eyes with progressive keratoconus, results were reported for 46 treated and 48 control eyes; at 36 months, Kmax had increased by a mean of 1.75 ± 0.38 D in untreated eyes and flattened by 1.03 ± 0.19 D in treated eyes. In the UK KERALINK trial, 60 patients aged 10 to 16 with progressive keratoconus were randomised to epithelium-off CXL plus standard care or standard care alone. At 18 months the adjusted difference in steep keratometry (K2) was −3.0 D in favour of CXL (95% confidence interval −4.9 to −1.1 D; P = 0.002). Progression, defined as a 1.5 D rise in K2, occurred in 2 of 30 treated patients (7%) and 12 of 28 standard-care patients (43%).
A 95% confidence interval is the range of true effects that are reasonably compatible with the data; here, even the least favourable end of the range still favours CXL. A P-value of 0.002 means a difference this large would be unlikely if CXL had no effect, but it says nothing on its own about how large or lasting the benefit is.
In practice, refer when sequential same-device tomography shows change beyond that device's repeatability in more than one parameter, when best-corrected acuity or refraction is changing in a way that fits the tomography, or when you are unsure. A borderline case referred early is easier to manage than an advanced case referred late.
What to include in a referral
- Age and date of birth, plus age at diagnosis if known.
- Sequential tomography from the same instrument, with dates, device name and the key values (anterior and posterior curvature, Kmax or K2, thinnest pachymetry). Attach the printouts or exports rather than summarising them.
- Refraction and best-corrected acuity over time, in spectacles and in contact lenses where relevant.
- Contact lens history, including lens type and how long lenses were out before each scan, as lens wear can alter anterior curvature readings.
- Eye rubbing history and atopy (eczema, asthma, hay fever), along with family history of keratoconus and relevant systemic conditions.
- Previous ocular surgery, especially refractive surgery.
- Whether the patient wishes to be considered for public care, private care or both.
Urgency: children and rapid progression
Keratoconus diagnosed in childhood or adolescence deserves a prompt referral. A 2026 European Reference Network (ERN-EYE) clinical consensus statement on paediatric keratoconus notes that the condition often advances rapidly in this age group and can significantly affect visual development, and it emphasises early detection, monitoring and family education. Some corneal surgeons will treat children at diagnosis rather than wait for documented progression; that is a decision for the ophthalmologist, so the referrer's job is not to delay while collecting a second set of scans. The same urgency applies at any age when progression is rapid or acuity is falling quickly. Sudden pain, redness and loss of vision in a keratoconic eye can indicate acute corneal hydrops and should be discussed with an eye department the same day.
Public and private pathways in New Zealand
Public referral is via a GP or optometrist to the local Health New Zealand | Te Whatu Ora eye department. Access, triage criteria and waiting times vary between regions, and there is no single national published threshold for CXL. In some regions public care is delivered through contracted private providers. Private referral can be made directly to a corneal ophthalmologist; patients should be told that private treatment involves costs and that insurance cover varies.
To help referrers and patients see who provides what, Keratoconus New Zealand maintains a directory of corneal surgeons and keratoconus providers in New Zealand, listing only the procedures each provider states it offers. For patients, the companion guide to keratoconus surgery and treatments in New Zealand explains the options in plain language.
Optometrist-led monitoring and scleral lens care
Cross-linking is one step in a longer pathway. Before referral, a keratoconus-focused optometrist documents the baseline, repeats tomography at intervals that are shorter for younger patients, manages eye rubbing and atopy, and provides the best achievable vision, most often with rigid or scleral contact lenses. After CXL, the cornea can continue to change for months; lenses are usually refitted once the surgeon is satisfied the surface has healed and readings have settled, and sequential tomography continues so that any further progression is picked up. Scleral lenses also remain the main visual rehabilitation for many patients after corneal ring segments or transplantation.
Keratoconus-focused optometrists practise across New Zealand. In Hamilton, keratoconus monitoring and specialty lens care are provided by the optometry team at Rose Optometry; the author is a partner in that practice. More detail is on the Rose Optometry keratoconus care page.
Limitations of this guidance
- The Global Consensus is expert opinion from 2015. It predates several newer CXL protocols and imaging methods, and it deliberately set no numerical thresholds.
- The randomised trials cited are small (60 patients in KERALINK, 100 eyes in the Melbourne trial) and tested epithelium-off CXL; results may not apply to other protocols.
- The ERN-EYE consensus is a European document; New Zealand services and populations differ.
- Public referral criteria and waiting times in New Zealand are set regionally and change over time; check your local eye department's current criteria.
- This is a narrative guide, not a systematic review, and the author has a declared interest as a partner in an optometry practice that provides keratoconus care.
About the New Zealand Eye Research Centre
The New Zealand Eye Research Centre is an independent clinical research centre at 37 Lake Road, Frankton, Hamilton 3204. It conducts and reviews eye research with a team trained in Good Clinical Practice (GCP). Enquiries can be sent to research@nzerc.com. Clinicians can read how to refer a patient to eye research, and families can read what taking part in eye research involves.
How to cite this article
Lallu J. Keratoconus referral pathways in New Zealand: a guide for optometrists and GPs. New Zealand Eye Research Centre; 21 November 2026. Available at: https://www.newzealandeyeresearch.com/post/keratoconus-referral-pathways-new-zealand-clinicians.
References
- Gomes JA, et al. Global consensus on keratoconus and ectatic diseases. Cornea. 2015. PMID 25738235. doi:10.1097/ICO.0000000000000408
- Wittig-Silva C, et al. A randomized, controlled trial of corneal collagen cross-linking in progressive keratoconus: three-year results. Ophthalmology. 2014. PMID 24393351. doi:10.1016/j.ophtha.2013.10.028
- Larkin DFP, et al. Effect of Corneal Cross-linking versus Standard Care on Keratoconus Progression in Young Patients: The KERALINK Randomized Controlled Trial. Ophthalmology. 2021. PMID 33892046. doi:10.1016/j.ophtha.2021.04.019
- Buzzonetti L, et al. Paediatric Keratoconus: An ERN-EYE Clinical Consensus Statement on Diagnosis, Treatment and Follow-Up Care. Ophthalmology and Therapy. 2026. PMID 42538519. doi:10.1007/s40123-026-01463-5





